NCT05464953

Suprachoroidal Triamcinolone Versus Posterior Subtenon Triamcinolone Alone or Formulated in the Management of Diabetic Macular Edema.

Alazher University Dean

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 75 (actual)
• Sponsor: Al-Azhar University · Academic / Other
• Sex: All
• Age: 40 Years – 69 Years
• Healthy volunteers: Not accepted

Summary

Background Retinal vascular disorders, such as diabetic retinopathy, hypertensive retinopathy, retinal hemorrhage, and retinal vein occlusion are significant causes of vision impairment and blindness worldwide. Diabetic retinopathy (DR) is the most common retinal vascular disorder and is the leading cause of vision loss among patients aged 25 to 74 years. Aim to compare formulated Posterior Subtenon Triamcinolone acetonide (PSTA) injection versus Posterior Subtenon Triamcinolone acetonide alone versus suprachoroidal triamcinolone in the management of diabetic macular edema.

Conditions

• Diabetic Macular Edema of Left Eye

Interventions

Type	Name	Description
DRUG	Triamcinolone Acetonide	Triamcinolone Acetonide is a corticosteroid that has antiangiogenic and anti-inflammatory effects that can inhibit the expression of VEGF and other proinflammatory cytokines, improving best-corrected visual acuity and decreasing central retinal thickness (CRT) in patients with macular edema
DRUG	Formulated Triamcinolone	Formulated Triamcinolone: is triamcinolone and sodium hyaluronate and chondroitin sulfate

Timeline

• Start date: 2020-01-20
• Primary completion: 2022-04-20
• Completion: 2022-04-30
• First posted: 2022-07-19
• Last updated: 2022-07-19

Locations

1 site across 1 country: Egypt